Showing results (211-220 of 242) with videos related to
Sort By:
Pageof 25
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.Cancer|October 3, 2014
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation ConsortiumLiza C Villaruz, Mark A Socinski, Shira Abberbock, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2014
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologiesMurry W Wynes, Trista K Hinz, Dexiang Gao, et al.The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.JTO Clinical and Research Reports|March 17, 2023
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLCMarcelo V Negrao, Vassiliki A Papadimitrakopoulou, Andrew C Price, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.Cancer Cell|October 20, 2023
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancerAnanda M Rodilla, Rajesh M Valanparambil, Philip C Mack, et al.Pageof 25